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Effort but not Reward Sensitivity is Altered by Acute Sickness
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Institute for Brain, Centre for Cognitive Neuroimaging, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands
Sickness behavior in humans is characterized by low mood and fatigue, which have been suggested to reflect changes in motivation
involving reorganization of priorities. However, it is unclear which specific processes underlying motivation are altered. We tested whether
bacterial endotoxin E. coli lipopolysaccharide (LPS) affected two dissociable constructs of motivational behavior, ie, effort and reward
sensitivity. After familiarization with 5 effort levels, participants made a series of accept/reject decisions on whether the stake offered (1, 4,
8, 12, or 15 apples) was ‘worth the effort’ (10%, 27.5%, 45%, 62.5%, and 80% of maximal voluntary contraction in a hand-held
dynamometer). Effort and reward levels were parametrically modulated to dissociate their influence on choice. Overall, 29 healthy young
males were administered LPS (2 ng/kg; n= 14) or placebo (0.9% saline; n= 15). The effort-stake task, and self-reported depression and
fatigue were assessed prior to LPS/placebo injection, 2 and 5 h post injection. Cytokines and sickness symptoms were assessed hourly till
8 h after LPS injection. LPS transiently increased interleukin-6 and tumor necrosis factor-α, sickness symptoms, body temperature and self-
reported fatigue, and depression post injection relative to baseline and placebo. These changes were accompanied by LPS-induced
decreases in acceptance rates of high-effort options, without significantly affecting reward sensitivity 2 h post injection, which were partially
recovered 5 h post injection. We suggest that LPS-induced changes in motivation may be due to alterations to mesolimbic dopamine. Our
behavioral paradigm could be used to further investigate effects of inflammation on motivational behavior in psychiatric and chronic
illnesses.
Neuropsychopharmacology (2018) 43, 1107–1118; doi:10.1038/npp.2017.231; published online 15 November 2017
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INTRODUCTION
Motivational symptoms such as apathy and fatigue are
common in patients with psychiatric disorders including
depression, schizophrenia, and bipolar disorder (Toomey
et al, 1998). A growing field of research suggests that
inflammation may contribute to these motivational symp-
toms (Felger and Treadway, 2017; Réus et al, 2015; Rosenblat
et al, 2014). This is supported by observations of elevated
levels of pro-inflammatory cytokines interleukin-6 (IL-6)
and tumor necrosis factor-α (TNFα) in people who suffer
from chronic major depression (Dowlati et al, 2010; Müller
and Schwarz, 2007; Young et al, 2014) and observations of
neuroinflammation in patients with bipolar disorder (Rao
et al, 2009; Stertz et al, 2013; Yüksel and Öngür, 2010) and
schizophrenia (Garver et al, 2003; Rosenblat et al, 2014).
Systemic inflammation in humans typically induces a
cluster of non-specific symptoms (ie, sickness behavior)
including fatigue, depression, and apathy (Dantzer, 2001).
Studies of sickness behavior in animals suggest that these
behavioral changes might be mediated by cytokine effects on
the central nervous system (Dantzer et al, 2014; Felger and
Miller, 2012; Swardfager et al, 2016). Following pathogen
exposure, pro-inflammatory cytokines are released by
activated immune cells to orchestrate the physiological
immunologic response (Dembic, 2015). These pro-
inflammatory cytokines also have a critical role in the
regulation of immune influences on brain function (Kronfol
and Remick, 2000) and have shown to affect dopamine
function in mesolimbic brain regions (Neurauter et al, 2008;
Capuron et al, 2012). Dopamine has repeatedly been
associated with both reward and effort-based decision
making, but it remains to be determined how inflammation
affects effort and reward influences on behavior.
Several human studies have investigated reward learning
and mesolimbic functioning after treatment with the
inflammatory cytokine interferon alpha (INFα) or acute
inflammation challenges. These studies demonstrated altered
reward learning (Harrison et al, 2015) and reductions in
reward-related ventral striatal activity, that was associated
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with inflammation-induced increases in depression, fatigue,
and anhedonia (Capuron et al, 2012; Dowell et al, 2016;
Eisenberger et al, 2010).
By contrast, research with animals suggest that inflamma-
tion affects effort expenditure, rather than reward processing
(Larson et al, 2002; Larson, 2006; Nunes et al, 2014; Yohn
et al, 2016). In a two-choice (high-effort/high-reward vs low-
effort/low-reward) paradigm (Salamone et al, 1994), admin-
istration of IL-1β shifted rodent’s choice towards the low-
effort/low-reward option. Importantly, reward sensitivity
remained intact as high-reward preferences were unaffected
(Nunes et al, 2014). Another study demonstrated that
inflammation reduced the overall effort investment (ie,
number of responses), whereas the better high-effort/high-
reward option was still favored (Vichaya et al, 2014). A
version of this latter paradigm was recently assessed in
humans where participants chose between high-effort/high-
reward and low-effort/low-reward options. Reward magni-
tude and probability was modulated (Lasselin et al, 2016).
Although participants selected the high-effort/high-reward
options at the same rate during inflammation compared to
placebo, they selected a greater proportion of the high-effort
options when the probability to win the reward was high.
Thus, participants still performed the high-effort options
during inflammation to gain a higher reward, suggesting that
they are still reward sensitive.
Paradigms used to date have been limited in the
dissociation of reward and effort influences as they typically
compare high-reward/high-effort options with low-reward/
low-effort options. Accordingly, in the current investigation,
we aimed to test whether systemic inflammation differen-
tially affects reward or effort processing in healthy human
volunteers using a recently developed effort-stake choice
paradigm (Bonnelle et al, 2015, 2016). In this paradigm, we
parametrically modulate effort and reward choices by
providing options with combinations of different levels of
reward and effort, allowing us to dissociate effort and reward
influences on choice.
Our second aim was to explore the relationship between
changes in motivational behavior and changes in fatigue and
depression or pro-inflammatory cytokine response. In-
formed by current literature highlighting the role of IL-1β,
IL-6, and TNFα in various chronic conditions that express
motivational symptoms, including in major depressive
disorder (Dowlati et al, 2010; Young et al, 2014; (Engler
et al, 2017; Felger and Treadway, 2017), rheumatoid arthritis
(Roerink et al, 2017a); and cancer-related fatigue (Bower and
Lamkin, 2013; Schubert et al, 2007; Smith et al, 2014; Wood
and Weymann, 2013; Roerink et al, 2017a), as well as the
effects of acute administration of IL-6 and IL-1β on animal
behavior (Nunes et al, 2014; Vichaya et al, 2014; Bonsall et al,
2015; Yohn et al, 2016), we focused our investigation on
these three pro-inflammatory cytokines.
MATERIALS AND METHODS
General Session Procedure
This study was part of a larger clinical trial at the department
of intensive care medicine of the Radboudumc in Nijmegen
in the Netherlands investigating the effects of human
endotoxemia followed by the administration of a live-
attenuated influenza vaccine ‘Fluenz’ on the immune
response (ClinicalTrials.gov: NCT02642237). The human
endotoxemia sessions took place 1 week before the admin-
istration of Fluenz and were therefore not confounded by
this second part of the clinical trial. Participants received
either E. coli-derived lipopolysaccharide (LPS) at a dose of
2 ng/kg or saline (0.9% NaCl) intravenously. They were
randomly assigned to the LPS or placebo condition on the
morning of testing by an unaffiliated research nurse and
deblinding of conditions took place after all data had been
collected. To control for individual differences in baseline
performance, behavioral testing took place at three time
points: session 1: 45 min before injection; session 2: 2 h post
injection and; session 3: 5 h post injection. ‘Timing was based
on previous experiences from our group showing that
sickness symptoms are limited 2 h after LPS administration,
whereas cytokine levels are still high (Kox et al, 2015;
Leentjens et al, 2012).’ All study procedures were in
accordance with the declaration of Helsinki, including the
latest revisions and approved by the local medical ethics
committee (CMO: 2015/2058).
Participants
Thirty healthy, non-smoking Caucasian males aged 18–35
years old (median age 21; IQR: 20–23) without any medical/
psychiatric history or current use of (prescription) drugs
were recruited by the Radboud University Medical Centre
Intensive Care Research Unit (see Table 1; Supplementary
Materials for inclusion and exclusion criteria). All subjects
were bachelor or master students from the local universities.
To reduce potential variation related to gender or hormonal
fluctuations in female menstrual cycle (Angele et al, 2014,
Engler et al, 2016, Karshikoff et al, 2015; Moieni et al, 2015),
only male subjects were used. Participants were asked to
refrain from food (12 h) as well as caffeine and alcohol (24 h)
before the LPS/placebo challenge. One volunteer was
excluded due to vomiting that interfered with task perfor-
mance during session 2 (LPS group: N= 14, placebo group:
N= 15).
Force-Level Familiarization
After estimation of maximum voluntary contraction (MVC)
(see Supplementary Materials for details on apparatus and
Table 1 Characteristics of Participants
LPS group
(n=14)
Placebo group
(n= 15)
Median IQR Median IQR p-value (between
groups t-test)
Age (years) 21 20–23 22 19–23 0.90
Height (cm) 180 178–188 186 178–189 0.16
Weight (kg) 75 70–84 79 71–87 0.65
BMI (kg/m)2 23 20–26 23 22–25 0.93
Abbreviation: IQR, interquartile range.
All participants were male.
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MVC estimation), the five effort levels were set as 10%,
27.5%, 45%, 62.5%, and 80% of each individual’s MVC, and
represented as sections on the trunk of an apple tree
(Figure 1b). Beginning at effort level 1, participants practiced
squeezing to the required force and holding their grip at that
force for 2 s (Figure 1c). The trunk of the tree filled up with
red as the dynamometer was squeezed, and turned yellow as
soon as the required force was reached. Each effort level was
Decision Phase 
Execution Phase 
YES decision (i.e. 
accepted offer) 
NO decision (i.e. 
rejected offer) 
Force-Level Familiarization 
NASA task-load 
index 
Calibration 
5 Stake levels:  
2, 4, 8, 12 or 16 
apples 
5 Effort levels:  
10%, 27.5%, 
45%, 62.5% or 
80% MVC 
Figure 1 (a) Example of the feedback participants saw during calibration phase. (b) Representation of how effort and stake levels were presented to
participants. Effort level was indicated by where the yellow line appeared on the tree’s trunk, starting at the bottom for effort level 1 and moving up to effort
level 5 at the top. In the example pictured effort is set at level 3 corresponding to 45% MVC. Stake level is indicated by the number of apples on the tree,
which ranged from 2 to 16 apples. In the example pictured stake is set at stake level 3 corresponding to 8 apples. (c) All the stages of the task that were
repeated during each session. In force-level familiarization stage, participants had to reach each effort level twice, starting at effort level one (pictured) and
moving up to effort level 5. They then completed the NASA task-load index questionnaire. During the decision phase, each of the 25 conditions were
presented four times each in a pseudo-random order. Participants just had to select YES or NO to each offer. For the execution phase, 26 trials from the
decision phase were randomly selected for the participant to perform. If an offer they had accepted (YES) was selected, they saw the command ‘start
squeezing!’ and were able to attempt to reach the force level required to win the apples. If an offer they had rejected (NO) was selected the message ‘offer
rejected’ appeared on the screen and they waited for the next trial to begin.
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performed twice sequentially from level 1 to level 5 using the
dominant hand. Force-level familiarizations were repeated at
the start of each session to remind participants of the effort
required for each level.
Experimental Task
Participants were presented with a series of offers, in the
form of the apple trees, and they had to select YES or NO, by
lightly squeezing the right or left dynamometer, depending
on if they evaluated the stake offered to be ‘worth the effort’.
Twenty-five possible offers (all combinations of the 5 effort
levels and 5 stake levels (1, 4, 8, 12, or 15 apples)) were each
sampled four times in a pseudo-random order, totaling 100
trials in each session (Figure 1).
To make each judgment behaviorally relevant, participants
were told that 26 decisions would be randomly
selected for them to perform immediately following the
decision phase. These 26 trials were then presented during an
execution phase. If the offer was accepted, participants had
5 s to reach the required effort level and hold it for 2 s. If they
were successful, they received feedback stating how many
apples they had won. If the offer was rejected, the tree
appeared on screen with the message ‘offer rejected’,
meaning they were not able to attempt to win the apples
offered (Figure 1c). Participants were told at the start of the
day they would be rewarded based on the number of apples
(worth 3 cents each) they gathered during this execution
phase. Ten trials were practiced before session 1 to
familiarize them with the stake/effort relationships. To
control for changes in perceived task demand, participants
performed a NASA task-load index questionnaire (Hart and
Staveland, 1988) after each familiarization session. Partici-
pants rated temporal, physical, and mental demand; frustra-
tion, effort required and their performance for each
effort level.
Measurement of Sickness Behavior and Mood
Physical sickness symptoms were measured before LPS
administration (T= 0) and at 30-min intervals until 8 h after
LPS administration (17 measures). Participants were asked to
rate from 0 (absent) to 5 (very severe) the severity of six
common symptoms: nausea, headache, muscle aches, back
pain, shivers, and vomiting. Self-reported mood was assessed
using the depression and fatigue subscales of the profile of
moods state questionnaire (POMS (McNair et al, 1971)) at
the start of each session (see Supplementary Materials for
details on the subscale items).
Measurement of Cytokines in Plasma
EDTA-anticoagulated blood was collected at: 1, 1.5, 2, 3, 4, 6,
and 8 h after LPS administration, centrifuged (2000 g, 4 °C,
10 min), and stored at − 80 °C until analysis. Plasma
concentrations of cytokines of interest (TNFα and IL-6)
were measured using a simultaneous (entered together in
one batch) Luminex assay (R&D systems; Abingdon Science
Park, UK, Human high sensitivity cytokine kit, catalog
numbers LHSCM000, LHSCM210, LHSCM206, www.
rndsystems.com). Statistical analyses to calculate plasma
concentrations were performed using Graphpad Prism
version 5.0 (Graphpad Software, San Diego, CA, USA).
Lower detection limits in plasma and intra-assay
coefficients of variation (C.V.) were; 0.22 pg/ml (C.V.
1.54%) for TNFα and o0.86 pg/ml (C.V. 0.92%) for IL-6.
We initially also aimed at assessing IL1-Ra and IL1-b because
of the suggested association between IL1 and fatigue
(Roerink et al, 2017a). Unfortunately, luminex assays of
IL1-Ra failed and measures were considered unreliable as
concentrations of IL1-Ra exceeded the upper detection limit
(415 296 pg/ml, C.V.= 0.046%). IL-1β was excluded from
analyses because plasma concentrations did not exceed lower
detection limits at 2 h post injection (0.79 pg/ml, C.
V.= 0.30%).
STATISTICAL ANALYSIS
Behavioral Task
The percentage of accepted offers for each of the 25
conditions (5 effort and 5 stake levels) was the key variable
for each participant. We first tested whether LPS induced a
change in choice behavior between session 1 and session 2.
Acceptance rates were entered into a 5 (effort level) × 5 (stake
level) × 2 (time) × 2 (groups) AVOVA. On the basis
of our hypothesis, we were specifically interested in whether
LPS affected effort and/or stake sensitivity. Accordingly, our
tests of interests were the effort × time × stake × group
interaction and, if significant, the effort × time × group and
stake × time × group interactions. If LPS induced a significant
change in choice behavior, we subsequently ran an
ANOVA comparing session 1 and session 3 to test whether
the LPS-induced changes in choice behavior recovered to
baseline.
These analyses were repeated with generalized estimating
equation (GEE) using a binary logistic model and exchange-
able working correlation structure, which is better suited for
binomially distributed categorical outcomes. Effort level,
stake level, and trial (1–100) were mean centered and entered
as continuous variables, session and group (LPS/placebo)
were entered as factors, and the model contained all main
effects and interactions.
Subjective Measures, Cytokines, and Physiology
A total score for sickness symptoms was calculated for each
subject at each time point. Febrile response and sickness
symptoms were entered into a repeated-measures ANOVA
with the factors time (17 levels) and group. Plasma
concentrations of cytokines (TNFα and IL-6) were entered
into a repeated-measures ANOVA with the factors time (8
levels) and group.
Total scores for depression and fatigue were calculated as
mean score on the POMS subscales for each session. A
repeated-measures ANOVA with the factors time (3 levels)
and group was performed for fatigue and depression scores
separately. Similar to our behavioral analysis, we first
assessed LPS-induced changes between session 1 and 2.
If significant, we assessed whether changes recovered to
baseline by comparing session 1 and 3. Post-hoc Bonferroni-
corrected independent t-tests were calculated, where
appropriate.
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Relationship Between Effort/Stake Sensitivity and Mood
and Cytokines
To assess whether LPS-induced changes in behavior were
associated with changes in mood and/or cytokines, we first
calculated the individual levels of effort and reward
sensitivity via a binomial logistic regression in Matlab with
effort and stake level as predictors and the decisions (yes/no)
as dependent variable for each subject. The β’s were
standardized by dividing by the standard error to minimize
the impact of inflated β’s (Apps et al, 2015) (Supplementary
Table S2). Change (session 2− session 1) in the standardized
β’s were used to assess relationships with LPS-induced
changes in mood and/or cytokines. Two stepwise multiple
regressions were used with change in effort sensitivity and
change in stake sensitivity as dependent variable. Change in
depression, change in fatigue, peak concentration of IL-6,
and peak concentration of TNFα were entered as predictor
variables in both regressions. All regressions were computed
using only data from the LPS group. Statistical threshold for
all stepwise multiple regression analyses were Bonferroni-
corrected for multiple comparisons.
Control Analyses
To assess whether LPS effects were explained by alterations
in perceived physical demand, we assessed LPS effects on
total scores of the NASA task-load index questionnaire (sum
of each section) using a repeated-measures ANOVA with the
factors effort, time, and group. We additionally assessed LPS
effects on the NASA task-load index subscales ‘physical
demand’ (How physically demanding was the task?) and
‘effort’ (how hard did you have to work to accomplish the
task?) using repeated-measures ANOVA with the factors
effort, time and group, and on the sickness symptom ‘muscle
aches’ using repeated-measures ANOVA with the factors
time and group. When no groups’ differences were found, we
tested whether LPS effects on behavior remained significant
when the NASA subscales or the sickness symptom ‘muscle
aches’ were added as covariate into the ANOVA on
acceptance rates.
Finally, we assessed the relationship between standar-
dized β’s from the binomial logistic regression and other
variables that may confound the behavioral results (ie, total
sickness symptoms, muscle aches, febrile response, NASA
physical demand, and NASA effort) within the LPS group
using Pearson’s correlation analysis. Total sickness symp-
toms and febrile response could not be added as covariate in
the ANOVA because they were significantly affected by LPS
(see ‘Results’) and therefore violate the assumption of
homogeneity of regression slopes (Miller and Chapman,
2001).
RESULTS
Behavioral Task
Results are presented in Figure 2 and Supplementary Tables
S1 and S2. As shown previously in healthy people (Bonnelle
et al, 2015, 2016), there were significant main effects of effort
and stake on acceptance rates, demonstrating that both
groups were sensitive to the effort and stake manipulations
(acceptance rates increase with higher stake and lower effort
levels) (stake: F(4,108)= 131.2, po0.001, effort: F(4,108)= 117.2,
po0.001).
LPS effects on stake differed significantly from LPS effects
on effort (stake × effort × time× group: (F(16,432)= 1.81,
p= 0.028), with significant group effects on effort-related
acceptance rates (effort × time× group: F(4,108)= 3.2,
p= 0.016), but not stake-related acceptance rates (stake×
time× group: F(4,108)= 0.4, p40.7). Breakdown of the inter-
action by group revealed that effort-related acceptance rates
were reduced in the LPS group (stake × effort × time:
F(16,208)= 3.12, po0.001; effort × time: F(4,56)= 4.93,
p= 0.002; stake× time: F(4,56)= 1.77, p= 0.15), but not in the
placebo group (stake× effort × time: F(16,208)= 1.17, p= 0.29;
effort × time: F(4,56)= 1.13, p= 0.34; stake × time: F(4,56)= 2.28,
p= 0.11). Further breakdown of the effort × time× group
interaction by session revealed that there was no between
group difference at session 1 on any of the effort levels (all
p40.05), and that the LPS group accepted less offers than the
placebo group for the highest effort level during session 2
(80%: T(27)=− 2.695, p= 0.012; 62.5%: T(27)=− 1.843,
p= 0.076). This between group difference on effort was not
present during session 3, compatible with partial recovery
(effort × stake× time× group: F(16,432)= 1.295, p= 0.196; ef-
fort × time× group (F(4,108)= 0.366, p= 0.833; stake × time×
group (F(4,108)= 0.999, p= 0.411).
These findings were confirmed with GEE (stake × effort ×
time × group: β=− 0.026, SD= 0.13, p= 0.043; effort ×
time × group: β=− 0.85, SD= 0.22, po0.001; stake × time ×
group: β= 0.36, SD= 0.19, p= 0.062). Breakdown of the
interaction by group revealed that effort but not stake-related
acceptance rates were reduced in the LPS group (stake ×
effort × time: β= 0.24, SD= 0.11, p= 0.021; effort × time:
β= 0.75, SD= 0.20, po0.001; stake × time: β=− 0.12, SD=
0.13, p= 0.35), whereas the trend observed for the stake ×
time × group interaction was driven by a trend in the placebo
group (stake × effort × time: β=− 0.02, SD= 0.08, p= 0.81;
effort × time: β=− 0.14, SD= 0.10, p= 0.17; stake × time:
β= 0.27, SD= 0.14, p= 0.053). Further breakdown of the
effort × time × group interaction by session revealed that
there was a between group difference at session 2 (stake ×
effort × group: β=− 0.31, SD= 0.13, po0.016; effort × group:
β= 1.03, SD= 0.25, po0.001; stake × group: β=− 0.46, SD=
0.24, p= 0.053) but not at session 1 (stake × effort × group:
β=− 0.066, SD= 0.23, p= 0.42) or session 3 (stake × effort ×
group: β=− 0.184, SD= 0.12, p= 0.14) (Supplementary
Tables S3 and S4).
Total rewards obtained in the execution phase ranged
between €2.67–€6.42 for session 1, €1.25–€6.39 for session 2,
and €1.41–€6.39 for session 3 and did not differ between
groups (all p40.05) (Supplementary Table S2). All subjects
were able to successfully perform all effort levels twice before
each session, indicating that LPS did not affect the ability to
perform high-effort trials.
Subjective Measures, Cytokines, and Physiology
LPS, but not placebo, induced an increase in sickness
symptoms (group × time: F(1,26)= 18.9, po0.001), which
peaked at 1.5 h post injection. Importantly, sickness symp-
toms were significantly higher in the LPS group relative to
the placebo group at session 2, whereas no group differences
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Figure 2 (a) The mean percentage of accepted offers during the decision phase for each of the 25 conditions (5 effort × 5 stake). Left column is results
from the LPS group, right column is results from the placebo group. Top row is results from session 1, middle row from session 2, and bottom row is from
session 3. (b) The mean percentage of accepted offers during session 2 collapsed across each effort (left) and stake (right) level. Error bars represent the
standard error of the mean. *po0.05 in a Student’s t-test.
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were observed at session 1 prior to injection, nor at session 3
at 5 h post injection (session 1 T(27)= 1.37, p40.1; session 2:
T(27)= 2.15, po0.05; session 3: T(27)= 0.30, p40.7, Figure 3a;
Supplementary Table S5).
LPS resulted in a 1± 0.6 °C (mean± SD) increase in
temperature (F(16,432)= 13.4, po0.001) and marked increases
in all cytokines of interest at session 2 (IL-6: F(7,189)= 32.48,
po0.001; TNFα: F(7,189)= 88.83, po0.001) (Figure 3b–d).
Temperature and cytokines reduced back to baseline by 8 h
from injection. The placebo group showed no change in any
of the cytokines throughout the whole recorded period.
LPS affected self-reported depression and fatigue levels
(depression time × group: F(1,27)= 10.997, p= 0.003; fatigue
time × group: F(1,27)= 23.6, po0.001). Specifically, the LPS
group reported feeling significantly more depressed and
fatigued than the placebo group during session 2 (depression:
T(27)= 3.609, po0.001; fatigue: T(27)= 4.806, po0.001 ), but
not session 1 (depression: T(27)= 1.517, p= 0.141; fatigue:
T(27)= 0.915, p= 0.368). The time × group interaction effect
was no longer significant for fatigue or depression when
looking at session 3 vs session 1 (depression: T(27)= 1.579,
p= 220; fatigue: T(27)= 2.477, po0.127). However, direct
comparisons revealed that the LPS group remained sig-
nificantly more depressed than the placebo group during
session 3, but only marginally more fatigued (depression:
T(27)= 2.221, p= 0.035; fatigue: T(27)= 1.942, p= 0.063)
suggesting only partial recovery for fatigue (Figure 4a).
Relationship Between Effort/Stake Sensitivity and Mood
and Cytokines
No relationship between changes in motivational behavior
and mood or cytokines were observed: POMS scores for
depression and fatigue, IL-6 or TNF did not remain in the
stepwise multiple regression analyses as significant predic-
tors for LPS-induced change in effort or stake sensitivity (all
p40.1, Supplementary Table S6).
Control Analyses
The LPS group did not differ from the placebo group on the
total NASA score or any of the NASA subscales (no
significant interaction effects, minimum p40.05, Figure 4b;
Supplementary Table S5) indicating that LPS did not affect
perceived (physical) demand of the requested effort levels.
LPS effects on muscle aches did not differ between the
groups (F(1,27)= 1.11, p= 0.30).
Adding the factor ‘physical demand’ as covariates to the
main analyses did not affect our main result (F(16,400)= 1.802,
p= 0.029), and no relationships were observed between
‘physical demand’ and effort sensitivity (r(14)= 0.34,
p= 0.02). However, adding the subscale ‘effort’ as covariate
to the main analyses resulted in a trend for the effort ×
stake × time interaction (F(16,400)= 1.65, p= 0.054).
Change in NASA effort was also marginally correlated with
change in effort sensitivity (r= 0.369, p= 0.053)
(Supplementary Table S6).
Adding muscle aches a covariate in the analysis of
decisions did not affect our main result (F(16,400)= 1.70,
p= 0.044, Supplementary Table S1). No relationships be-
tween LPS effects on behavior and muscle aches, total
sickness symptoms, and febrile response were observed (all
p40.05, Supplementary Table S6).
DISCUSSION
In this study, we used a relatively new paradigm that
parametrically modulates offers with respect to stake and the
Figure 3 (a) Time course of mean total sickness symptoms scores. (b) Time course of febrile response. (c) Time course of mean plasma cytokine level for
IL-6. (d) Time course of mean plasma cytokine level for TNFα. Error bars represent the standard error of the mean.
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effort required to obtain that reward (Bonnelle et al, 2015,
2016). We demonstrate that experimentally induced endo-
toxemia using LPS in humans reduces otherwise healthy
participant’s willingness to accept high-effort options, with-
out significantly altering reward sensitivity.
It has been suggested that sickness behavior is an adaptive
motivational state that involves reprioritization of the costs
and benefits of expending effort, rather than simply being
general physical weakness (Dantzer, 2001). Our results
support this claim: LPS reduced acceptance rates of high-
effort options, whereas the ability to perform the task was
not changed. All participants were able to successfully
perform the effort levels during a familiarization phase prior
to their decisions and participants reported no differences in
perceived demand to perform the task as indexed by the
NASA task-load index. This suggests that the changes we
observed are due to altered motivation, rather than a change
in physical strength or ability.
Changes in motivation are common across a broad
range of psychiatric and medical conditions (Fervaha et al,
2015; Kostić and Filippi, 2011; Sinha et al, 2013; Starkstein
and Pahissa, 2014). There is increasing evidence that
inflammation may have an important role in development
of amotivated states (Leboyer et al, 2012; Miller et al,
2009; Potvin et al, 2008; Réus et al, 2015; Bonaccorso et al,
2001; Capuron et al, 2012; Majer et al, 2008; Wichers
et al, 2005). Here, we found that LPS increased cytokines
and concomitantly altered motivational behavior and
mood supporting the concept that inflammation could
have a role in development of symptoms such as
depression and fatigue (Dowell et al, 2016; Engler et al,
2017; Felger and Treadway, 2017; Karshikoff et al, 2017;
Miller and Raison, 2016).
However, we could not demonstrate direct relationships
between LPS-induced behavioral changes and cytokine
concentrations or mood. This could be due to our small
sample size, lacking the power to detect such associations.
In addition, the immune manipulation we used (LPS)
induced robust increases with little variation in multiple
cytokines that strongly interact with one another, making
it difficult to disentangle which cytokine is responsible for
the observed change in behavior. Future studies that
induce more variation, eg, by using different dosages or
selectively stimulate or inhibit cytokines could provide
more insight on the role of specific cytokines on change in
behavior. Although many studies have suggested relation-
ships between motivational behavior and mood, actual
reports of these relationships have been limited (Lasselin
et al, 2016; Salamone et al, 2016). One reason for this
could be that the POMS was not sensitive enough to detect
subtle alterations in depressive mood and fatigue. Alter-
natively, because our task dissociated between the sub-
constructs of motivation (effort and reward) (Berridge et al,
2009), it may have captured behavior that is not necessarily
reflected by the subjective reports of fatigue and depression
(Karshikoff et al, 2017).
To the best of our knowledge, there has only been one
previous human study that investigated effort and reward
processing during inflammation (Lasselin et al, 2016). That
pioneering investigation used two-option choices (high-
reward/high-effort vs low-reward/low-effort) and showed
that after LPS the high-effort option was still favored, more
so when the probability of gaining the reward was also high.
There was no difference between LPS and placebo
conditions in the number of high-effort choices. Although
our results may at first appear to contradict these findings,
both studies demonstrated that reward sensitivity was not
affected by LPS. In addition, the two studies differed in
important ways.
First, in Lasselin et al’s forced-choice design, participants
had to perform an action on each trial (meaning they
updated their experience of the effort options), and they
Figure 4 (a) Mean profile of mood state (POMS) score for the fatigue (left) and depression (right) subscales for each session. (b) Total NASA task-load
index score for each effort level for session 1 (left) and session 2 (right). Error bars represent standard error of the mean. *po0.05 in a Student’s t-test.
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chose to perform the high-effort actions to gain a higher
reward at the same rate as after placebo. In our design,
participants only had the option to perform actions they
considered ‘worth the effort’ for the reward offered, ie, they
could choose to do nothing, which led to a reduction in
choice of high-effort options during inflammation. Further-
more, our paradigm parametrically modulated effort and
reward, rather than offering two-option choices. In this
way, our task allowed participants to gain the high rewards
at a lower effort level, meaning gaining the largest reward
was not contingent on putting in the highest effort. Second,
the previous human study (Lasselin et al, 2016) had a
probability dimension, the likelihood of gaining the reward
on high-effort trial was variable, an aspect which we did not
test. Our task was simpler: reward was always given if the
participant reached the effort level required. Finally, the
previous investigation tested their participants 4 h post LPS,
while we tested participants 2 h post LPS, which might be
why our subjects were more effort sensitive. Indeed, the
alterations in effort sensitivity were partly recovered 5 h
after LPS.
One potential mechanisms through which cytokines
can affect motivational behavior is through interference
with brain dopamine function (Felger and Treadway,
2017). Indeed, effort- and reward-related components of
motivated behavior have consistently been linked to
dopamine signaling (Chong et al, 2015; Skvortsova et al,
2017; Wardle et al, 2011). For example, using a variation
of the task reported here, Chong et al 2015 observed that
patients with Parkinson’s disease, who often experience
motivational symptoms, were willing to put in more
effort to gain rewards when they were ON dopaminergic
drugs compared to when they were OFF them. Animal
work has also shown that dopamine depletion in the
nucleus accumbens causes similar changes in effort-based
choice behavior as observed here (Randall et al, 2012).
However, previous neuroimaging work has mainly
focused on LPS effects on reward-related processes,
showing reduced reward-related signals in the ventral
striatum (Capuron et al, 2012; Eisenberger et al, 2010;
Harrison et al, 2015). Given the partial dissociable brain
networks of effort and reward processing (Klein-Flügge
et al, 2016; Skvortsova et al, 2014), the neural alterations
related to LPS effects on effort-based choice remained to
be determined. We unfortunately do not have brain
imaging data to compare to previous work (Capuron
et al, 2012; Eisenberger et al, 2010; Harrison et al, 2015).
Future studies are needed to better dissociate the neural
mechanisms of inflammation effects on effort- and
reward-related processes.
Insights into immune-to-brain pathways gained from
acute immune manipulation studies are important for
better mechanistic understanding of motivational deficits
in psychiatric conditions, and could lead to new pharma-
ceutical targets. Indeed, dopamine enhancing drugs like
methylphenidate or levodopa can reverse inflammation
effects (Yohn, 2016; Bonsall, 2015; Felger et al, 2015) and
has some effects on reducing fatigue in humans
(Blockmans et al, 2006; Kerr et al, 2012; Mendonça et al,
2007; Minton et al, 2011). It remains to be investigated
whether other dopamine manipulations would also reverse
inflammation effects on motivational symptoms. Here we
show that our task is sensitive to immune manipulation on
dissociable sub-constructs of motivational behavior
(reward and effort) in humans. This paradigm is
therefore promising for further human research on
immune-mediated changes in motivational behavior, and
for testing of pharmacological targets to treat motivational
symptoms. These could include targets at the immunolo-
gical level by inhibiting pro-inflammatory cytokines; a
method that has reduced fatigue symptoms in some
medical conditions (Omdal and Gunnarsson, 2005;
Roerink et al, 2017b), but also targets at the central level,
affecting dopamine function, for patients groups in
which immune-alterations are less prominent (Roerink
et al, 2017a).
This study has several limitations. First, the sample size
was small, lacking power to detect relevant associations
between individual immune responses, motivated behavior,
and mood. Second, we used a relatively high dose of LPS
(2 ng/kg). This inherently also induce sickness symptoms
that could affect the blindness of the conditions and
potentially confound task performance. Although we show
that our effects are specific to effort and not reward-based
decisions, and that sickness symptoms were not directly
correlated with effort-based choice within the LPS group, it is
unfortunately statistically impossible to dissociate sickness
symptoms from behavioral alterations, as these factors are
not independent (Miller and Chapman, 2001). Simply lowing
the dose might not help as this inherently also reduces the
behavioral effects, while still inducing significant increases in
sickness symptoms (Benson et al, 2017). Instead, future
studies might potentially be able to dissociate these factors,
eg, by assessing effects of co-administration with centrally
acting drugs that do not affect sickness symptoms. Finally,
we tested only men, whereas clinical work indicates that
motivational symptoms such as depression are more prone
in woman (Altemus et al, 2014). In addition, several studies
highlight the importance of sex differences in immune–brain
interactions that likely mediate the LPS effects on mood and
behavior (Engler et al, 2016; Karshikoff et al, 2015; Moieni
et al, 2015). This, therefore, limits generalizability of our
results.
In summary, experimental endotoxemia reduced, other-
wise, healthy participant’s willingness to engage in high-
effort options, while reward sensitivity was not significantly
altered. This change in motivation was not due to the task
being perceived as more effortful. Endotoxemia concomi-
tantly induced an increase in subjective reports of depression
and fatigue. The behavioral paradigm used in this study
provides a human model to further investigate brain
mechanisms underlying inflammation effects on motiva-
tional behavior. A better understanding of these mechanisms
in humans will be important for further development and
testing of pharmaceutical targets to treat motivational deficits
in psychiatric disorders.
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